Burzynski Research Institute (BZYR) Enterprise Value (2010 - 2025)
Burzynski Research Institute (BZYR) posted Enterprise Value of -$2165.0 for Q4 2025, down 132.55% sequentially from -$931.0 in Q3 2025, and down 253.18% YoY from $1413.4 in Q4 2024.
Burzynski Research Institute (BZYR) Enterprise Value (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Enterprise Value for 16 years, with the latest figure at -$2165.0 in Q4 2025.
- Quarterly Enterprise Value fell 253.18% year-over-year to -$2165.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was -$2165.0 (down 253.18% YoY) and the FY2025 annual result came in at -$847.0, up 35.34% from the prior year.
- Enterprise Value declined to -$2165.0 in Q4 2025 per BZYR's latest filing, from -$931.0 in the prior quarter.
- Over five years, Enterprise Value peaked at -$62.0 in Q1 2021 and troughed at -$5765.0 in Q4 2021.
- A 5-year average of -$1501.2 and a median of -$932.5 in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value tumbled 5354.84% in 2022, then surged 96.89% in 2023.
- Over 5 years, Enterprise Value stood at -$5765.0 in 2021, then surged by 70.65% to -$1692.0 in 2022, then surged by 46.04% to -$913.0 in 2023, then surged by 32.86% to -$613.0 in 2024, then plunged by 253.18% to -$2165.0 in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$2165.0, -$931.0, and -$821.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | -2,165.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | -2,165.00 |
| Aug 31, 2025 | -931.00 |
| May 31, 2025 | -821.00 |
| Feb 28, 2025 | -847.00 |
| Nov 30, 2024 | -613.00 |
| Aug 31, 2024 | -1,216.00 |
| May 31, 2024 | -297.00 |
| Feb 29, 2024 | -1,310.00 |
| Nov 30, 2023 | -913.00 |
| Aug 31, 2023 | -1,397.00 |
| May 31, 2023 | -148.00 |
| Feb 28, 2023 | -934.00 |
| Nov 30, 2022 | -1,692.00 |
| Aug 31, 2022 | -1,266.00 |
| May 31, 2022 | -4,766.00 |
| Feb 28, 2022 | -3,382.00 |
| Nov 30, 2021 | -5,765.00 |
| Aug 31, 2021 | -904.00 |
| May 31, 2021 | -594.00 |
| Feb 28, 2021 | -62.00 |